Latest Security News

Rhythm Biosciences reported a $2.26 million half-year loss as it advances ColoSTAT into commercialisation and expands geneType partnerships, signalling a pivotal phase for the ASX-listed medical diagnostics company.

Kaili Resources has reported encouraging initial pXRF results from its latest aircore drilling campaign targeting rare earth elements in South Australia's Mallee Project. Full assay results are pending, setting the stage for expanded exploration.

Nyrada Inc. reported a $3.19 million loss for the half-year ending December 2025, while advancing its lead drug candidate Xolatryp® into Phase IIa clinical trials targeting heart attack treatment.

Knosys Limited reported a 4.6% revenue increase to $5.07 million for the half-year ending December 2025, driven by stronger licence and project fees. However, the company’s net loss widened significantly to $1.53 million, reflecting heavy investment in its next-generation Libero X library management system.

PathKey.AI Ltd has responded to ASX inquiries about a recent spike in its share price and trading volume, confirming no undisclosed information is driving the market activity. The company points to its recent strategic update and funding completion as context for investor interest.

Orthocell has secured a $3 million R&D tax refund, lifting its cash reserves to nearly $50 million and reinforcing its financial strength as it pushes commercialisation of its nerve repair product Remplir™ across key global markets.

Neometals Ltd has reported impressive new copper assay results from its historic Rinaldi workings within the Barrambie Gold Project, setting the stage for imminent drilling to explore this high-grade opportunity further.

Cyclopharm has achieved a key milestone with Technegas approved for clinical use at the US National Institutes of Health, marking a strategic advance in its American expansion. Installation is imminent, leveraging a federal procurement framework that could broaden Technegas applications beyond pulmonary embolism.

Judo Capital Holdings Limited has announced a quarterly distribution of AUD 1.825 per capital note, fully franked and payable on 18 May 2026. The payment reflects a calculated yield based on prevailing market rates and remains subject to company discretion.

IDT Australia reports a robust 20.3% increase in core revenue and a dramatic narrowing of EBITDA losses, signalling early success from its strategic realignment under new leadership.

PhosCo Ltd has raised $5 million through a strongly supported share placement to fund exploration and development at its Gasaat Phosphate Project in Tunisia, positioning the company for upcoming resource milestones.

Solvar Limited reported a 5.8% rise in net profit for the half year ending December 2025, driven by strategic asset sales and expanded funding facilities. The company declared both interim and special dividends, signalling confidence despite ongoing regulatory challenges.